• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form F-4 filed by Voyager Acquisition Corp

    7/16/25 8:27:29 PM ET
    $VACH
    Get the next $VACH alert in real time by email

    Unavailable

    Get the next $VACH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VACH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VACH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology

    ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY – September 30, 2025 -- VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, "Voyager")), and Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, today announced a strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs). The combination of both technology platforms aims to unlock novel targeted therapies for the treatment of autoimmune and chronic immune diseases AOCs combine the specificity of monoclonal anti

    9/30/25 8:00:00 AM ET
    $VACH

    VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

    ZURICH, SWITZERLAND, July 17, 2025 -- VERAXA Biotech AG ("VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp.,  a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ:VACH, "Voyager" or the "SPAC")), announced today the filing of a registration statement on Form F-4 (the "Registration Statement"), which includes a preliminary proxy statement, with the U.S. Securities and Exchange Commission ("SEC") in regards to the proposed Business Combination Agreement announced April 23, 2025. "We are excited to share this pivotal milestone in VERAXA's journey toward becoming a publi

    7/17/25 1:00:00 AM ET
    $VACH

    VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform

    ZURICH, SWITZERLAND, May 29, 2025 -- VERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, "Voyager")), announced today it will be attending the upcoming ASCO Annual Meeting and BIO International Convention. At the conferences, Christoph Antz, CEO, and additional members of the VERAXA leadership team will be meeting with potential partners and investors, showcasing the Company's novel Bi-targeted Tumor-Associated Cytotoxicity (BiTAC) platform, and sharing the Company's growth plans as it prepares to list on the NASDAQ later this year. VERAXA is leveraging its proprietary BiTAC p

    5/29/25 10:34:13 AM ET
    $VACH

    $VACH
    SEC Filings

    View All

    SEC Form 425 filed by Voyager Acquisition Corp

    425 - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)

    9/5/25 9:32:08 AM ET
    $VACH

    Voyager Acquisition Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)

    9/5/25 9:31:27 AM ET
    $VACH

    SEC Form 10-Q filed by Voyager Acquisition Corp

    10-Q - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)

    8/14/25 4:05:44 PM ET
    $VACH

    $VACH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Voyager Acquisition Corp

    SC 13G - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)

    11/14/24 5:32:56 PM ET
    $VACH

    SEC Form SC 13G filed by Voyager Acquisition Corp

    SC 13G - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)

    11/14/24 1:17:46 PM ET
    $VACH

    Amendment: SEC Form SC 13G/A filed by Voyager Acquisition Corp

    SC 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)

    11/6/24 3:00:45 PM ET
    $VACH